Clinical trials: Urinary System Tumor
Disease Progression
Treatment Resistance Following Anti-cancer Therapies
The TRANSLATE study aims to better understand why tumors become resistant to standard anti-cancer therapies. New tumor biopsy and blood samples are collected after disease progression on standard-of-care anti-cancer treatment and…
- Trial name
- NCT04436120
- Testing
- De novo tumor tissue biopsy, Research blood draws
- Where
- 33 sites in United States, Argentina and 3 more
- Volunteers
- 38 people
- Sponsor
- Pfizer
Renal Cell Carcinoma
Temsirolimus (Torisel) Drug Use Investigation (Regulatory Post Marketing Commitment Plan)
The objective of this investigation is to determine the following items in all patients receiving Torisel for a certain period after marketing: 1. Confirmation of efficacy and safety for medical practice use. 2.
- Trial name
- NCT01210482
- Testing
- Temsirolimus
- Where
- Japan
- Volunteers
- 1,050 people
- Sponsor
- Pfizer
Advanced Ovarian Carcinoma, Advanced Renal Cell Carcinoma
First-in-human Phase I Study to Evaluate Safety, Tolerability and Antineoplastic Activity of OATD-02 in Patients With Selected Advanced and/or Metastatic Solid Tumours
The goal of this clinical trial is to learn if the OATD-02 administration (orally) in monotherapy is safe and has the pharmacodynamic potential to restore and enhance tumour responses to immunotherapy through increased arginine…
- Conditions
- Advanced Ovarian Carcinoma, Advanced Renal Cell Carcinoma, Advanced Pancreatic Carcinoma, Advanced Colorectal Carcinoma
- Trial name
- NCT05759923
- Testing
- OATD-02
- Where
- 3 sites in Poland
- Volunteers
- 40 people
- Sponsor
- Molecure S.A.
Solid Tumor, Renal Cell Carcinoma
A Study of BPI-452080 in Subjects With Solid Tumors
This open-label Phase 1 study will evaluate the efficacy and safety of BPI-452080 in patients with Solid Tumors
- Conditions
- Solid Tumor, Renal Cell Carcinoma, Von Hippel-Lindau Disease
- Trial name
- NCT05843305
- Testing
- BPI-452080
- Where
- 5 sites in China
- Volunteers
- 87 people
- Sponsor
- Betta Pharmaceuticals Co., Ltd.
Metastatic Solid Tumor, Recurrent Solid Tumor
A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors
The purpose of this study is to find out whether the study drug, LY4052031, is safe, tolerable and effective in participants with advanced, or metastatic solid tumors including urothelial cancer.
- Conditions
- Metastatic Solid Tumor, Recurrent Solid Tumor, Advanced Solid Tumor, Urinary Bladder Neoplasm
- Trial name
- NEXUS-01 (NCT06465069)
- Testing
- LY4052031, Pembrolizumab
- Where
- 39 sites in United States, Australia and 6 more
- Volunteers
- 460 people
- Sponsor
- Eli Lilly and Company
Bladder Cancer
Survivin Urine mRNA Assay Risk of Bladder Cancer Study
The purpose of this clinical trial is to evaluate the ability of urinary Survivin mRNA measurement to estimate the risk of bladder cancer at the time of cystoscopy in subjects with no prior history of bladder cancer presenting…
- Trial name
- NCT00315653
- Where
- United States
- Volunteers
- 600 people
- Sponsor
- Fujirebio Diagnostics, Inc.
Gastroesophageal Cancer (GC), Hepatocellular Carcinoma (HCC)
A Phase 1 Study of the Safety and Tolerability of CTX-10726
This is a Phase 1, open-label, first-in-human study of CTX-10726 monotherapy in patients with metastatic or locally advanced malignancies.
- Conditions
- Gastroesophageal Cancer (GC), Hepatocellular Carcinoma (HCC), Endometrial Cancer, Renal Cell Carcinoma (RCC)
- Trial name
- NCT07419841
- Testing
- CTX-10726
- Where
- 8 sites in United States
- Volunteers
- 70 people
- Sponsor
- Compass Therapeutics
Solid Tumor Malignancies, Cancer, Solid Cancers
A Phase I Study of LXP1788 Injection with Advanced Solid Tumors.
A Phase I, open-label, first-in-human study to determine the MTD, recommended phase 2 dose (RP2D), assess the safety, tolerability, pharmacokinetics and preliminary anti-tumor activity of LXP1788 Injection in patients with…
- Conditions
- Solid Tumor Malignancies, Cancer, Solid Cancers, Solid Tumor Cancer, Solid Tumor, Unspecified, Adult
- Trial name
- NCT06883539
- Testing
- LXP1788 is administered intravenously via Port-A
- Where
- 2 sites in Taiwan
- Volunteers
- 24 people
- Sponsor
- LaunXP Biomedical Co., Ltd.
Renal Cell Carcinoma
Tumor Registry of Advanced Renal Cell Carcinoma
The purpose of this registry is to record information of therapy reality of metastatic or locally advanced Renal Cell Carcinoma by office-based medical oncologists in Germany.
- Trial name
- RCC-Registry (NCT00610012)
- Where
- Germany
- Volunteers
- 1,500 people
- Sponsor
- iOMEDICO AG
Bladder Cancer
Clinical Investigation of the Multi4 System
A Clinical Investigation to Confirm Performance and Safety of the Multi4 System in Patients with Suspected Recurrent Bladder Cancer Lesions
- Trial name
- NCT06136312
- Testing
- Multi4
- Where
- Sweden
- Volunteers
- 18 people
- Sponsor
- Multi4 Medical Ab
Renal Cell Cancer
A Study of ABT-751 in Patients With Renal Cell Cancer
The purpose of the study is to determine if ABT-751 will decrease tumors, and determine how long the tumor shrinkage can be maintained in patients with renal cell cancer. Patients will receive ABT-751 by mouth daily for 21 days.
- Trial name
- NCT00073112
- Testing
- ABT-751
- Where
- 23 sites in United States, Canada
- Volunteers
- 60 people
- Sponsor
- Abbott
Cancer
Clinical Study of Pan-cancer DNA Methylation Test in Plasma
We intend to establish an efficient method for plasma cfDNA extraction and Bisulfite transformation to facilitate the detection of DNA methylation status using multiplex fluorescence PCR.
- Trial name
- NCT05685524
- Testing
- DNA methylation test
- Where
- China
- Volunteers
- 3,000 people, healthy volunteers welcome
- Sponsor
- Wuhan Ammunition Life-tech Co., Ltd
Oncology, Solid Tumor
Live Biotherapeutic Product MRx0518 and Pembrolizumab Combination Study in Solid Tumors
This is an open label, safety and preliminary efficacy study of MRx0518 in combination with pembrolizumab in patients with solid tumours (non small cell lung cancer, renal cell carcinoma, bladder cancer or melanoma).
- Conditions
- Oncology, Solid Tumor, Non Small Cell Lung Cancer, Renal Cell Carcinoma
- Trial name
- NCT03637803
- Testing
- MRx0518, Pembrolizumab 25 MG/1 ML Intravenous Solution [KEYTRUDA]
- Where
- 5 sites in United States
- Volunteers
- 63 people
- Sponsor
- 4D pharma plc
Non-muscle Invasive Bladder Cancer (NMIBC)
Evaluating the Safety and Performance of the Eight Medical Hyperthermia System IV 1.0 for HIVEC in NMIBC.
The goal of this clinical trial is to evaluate the safety and performance of the Eight Medical Hyperthermia System IV 1.0 when used to deliver recirculating hyperthermic intravesical chemotherapy (HIVEC) with mitomycin C (MMC) in…
- Trial name
- NCT07758881
- Testing
- Hyperthermic intravesical chemotherapy (HIVEC)
- Where
- 2 sites in Belgium
- Volunteers
- 30 people
- Sponsor
- Eight Medical International BV
Bladder Cancer
Efficacy and Safety of Multi-Instillations of Apaziquone in Patients With Non-Muscle Invasive Bladder Cancer
This is an international, multicenter, double-blind, placebo-controlled, randomized study. All eligible patients entering the open label phase of the study will receive a single immediate instillation of apaziquone (4 mg in 40 mL…
- Trial name
- NCT01410565
- Testing
- Apaziquone
- Where
- 47 sites in United States, Canada
- Volunteers
- 66 people
- Sponsor
- Spectrum Pharmaceuticals, Inc
Metastatic Renal Cell Carcinoma
Sutent Rechallenge In mRCC Patients
Retrospective and prospective study in mRCC patients treated with sutent in first line and rechallenged by Sutent in 3rd and 4th line.
- Trial name
- RESUME (NCT01827254)
- Testing
- sunitinib: observational study
- Where
- 18 sites in France
- Volunteers
- 61 people
- Sponsor
- Pfizer
Carcinoma, Renal Cell
A Study of Belzutifan (MK-6482) in Combination With Lenvatinib Versus Cabozantinib for Treatment of Renal Cell Carcinoma (MK-6482-011)
This study will compare the efficacy and safety of belzutifan + lenvatinib versus cabozantinib in participants with advanced renal cell carcinoma (RCC) with clear cell component after prior therapy.
- Trial name
- NCT04586231
- Testing
- Belzutifan, Lenvatinib, Cabozantinib
- Where
- 184 sites in United States, Argentina and 23 more
- Volunteers
- 747 people
- Sponsor
- Merck Sharp & Dohme LLC
Advanced Solid Tumors, Gastric Cancer
Open-Label, Dose-Finding Study Evaluating Safety and PK of FPA144 in Patients With Advanced Solid Tumors
This is a three-part, open-label, safety, tolerability, and PK study of FPA144. Patients will be enrolled in Part 1 (A or B, dose escalation) or Part 2 (dose expansion) of the study, but not both.
- Conditions
- Advanced Solid Tumors, Gastric Cancer, Transitional Cell Carcinoma of the Bladder
- Trial name
- NCT02318329
- Testing
- FPA144
- Where
- 26 sites in United States, South Korea and 1 more
- Volunteers
- 79 people
- Sponsor
- Five Prime Therapeutics, Inc.
Renal Cell Carcinoma
Temsirolimus Versus Sorafenib As Second-Line Therapy In Patients With Advanced RCC Who Have Failed First-Line Sunitinib
This is an international, randomized, open-label, outpatient, multicenter study. Subjects will be assigned in a 1:1 ratio to 1 of 2 treatment arms: temsirolimus 25 mg once weekly by intravenous (IV) infusion or sorafenib 400 mg…
- Trial name
- INTORSECT (NCT00474786)
- Testing
- Sorafenib, temsirolimus (Torisel)
- Where
- 128 sites in United States, Argentina and 18 more
- Volunteers
- 512 people
- Sponsor
- Pfizer
Carcinoma, Renal Cell, Metastases, Neoplasm
Combination of Capecitabine and GTI-2040 in the Treatment of Renal Cell Carcinoma
This phase II, 43 patient trial, will evaluate the efficacy of GTI-2040, an antisense oligonucleotide complementary to the R2 component of ribonucleotide reductase (RNR) mRNA, in combination with capecitabine, in the setting of…
- Trial name
- NCT00056173
- Testing
- GTI-2040
- Where
- 10 sites in United States
- Volunteers
- 43 people
- Sponsor
- Aptose Biosciences Inc.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.